Association of JNK1 with p21waf1 and p53: Modulation of JNK1 activity

Molecular Carcinogenesis

Volumn 36, Issue 1, 2003, Pages 38-44

  Xue, Yue ^a   Ramaswamy, Nadja T ^a   Hong, Xiaoman ^a   Pelling, Jill C ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

C jun amino terminal kinase 1; p21waf1; p53

Indexed keywords

MUTANT PROTEIN; PROTEIN P21; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL LINE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVITY; ENZYME ASSAY; EXPRESSION VECTOR; FIBROBLAST CULTURE; GENETIC CODE; GENETIC TRANSFECTION; MOLECULAR GENETICS; NONHUMAN; NULL CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RAT; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; CELL COMMUNICATION; CELL LINE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASES; RATS; TUMOR SUPPRESSOR PROTEIN P53;

MAMMALIA; TRIXIS; VECTORS;

EID: 0037225749     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10096     Document Type: Article

References (33)

1. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
2. Kastan MB, Zhan Q, el-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-597.
3. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-16.
4. Lane DP. Cancer. A death in the life of p53. Nature 1993; 362:786-787.
5. Asschert JG, Vellenga E, De-Jong S, de-Vries EG. Mutual interactions between p53 and growth factors in cancer. Anticancer Res 1998;18:1713-1725.
6. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-708.
7. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-456.
8. Scheffner M. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol Ther 1998;78:129-139.
9. Wyllie A. Apoptosis. Clues in the p53 murder mystery. Nature 1997;389:237-238.
10. Wang X, Ohnishi T. p53-dependent signal transduction induced by stress. J Radiat Res Tokyo 1997;38:179-194.
11. Cox LS. Multiple pathways control cell growth and transformation: Overlapping and independent activities of p53 and p21Cip/WAF1/Sdi1. J Pathol 1997;183:134-140.
12. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-825.
13. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993;6366:701-704.
14. Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 1993;366:707-710.
15. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816.
16. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-578.
17. Shim J, Lee H, Park J, Kim H, Choi EJ. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 1996;381:804-806.
18. WAF1 is dynamically associated with JNK in human T-lymphocytes during cell cycle progression. J Cell Sci 1998;111:2247-2255.
19. Davis RJ. MAPKs: New JNK expands the group. Trends Biochem Sci 1994;19:470-473.
20. Adler V, Pincus MR, Brandt-Rauf PW, Ronai Z. Complexes of p21RAS with JUN N-terminal kinase and JUN proteins. Proc Natl Acad Sci USA 1995;92:10585-10589.
21. Gupta S, Campbell D, Derijard B, Davis RJ. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995;267:389-393.
22. Milne DM, Campbell LE, Campbell DG, Meek DW. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation- induced protein kinase characteristic of the c-Jun kinase, JNK1. J Biol Chem 1995;270:5511-5518.
23. Adler V, Pincus MR, Minamoto T, et al. Conformation- dependent phosphorylation of p53. Proc Natl Acad Sci USA 1997;94:1686-1691.
24. Fuchs SY, Adler V, Buschmann T, et al. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev 1998;12:2658-2663.
25. Fuchs SY, Adler V, Pincus MR, Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA 1998; 95:10541-10546.
26. Hu MC, Qiu WR, Wang YP. JNK1, JNK2 and JNK3 are p53 N- terminal serine 34 kinases. Oncogene 1997;15:2277-2287.
27. 2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol 2001;21:2743-2754.
28. Ramaswamy NT, Pelling JC. Mutational status of the p53 tumor suppressor gene modulates the basal level of Jun amino terminal kinase (JNK) and its inducibility by UV irradiation in A1-5 rat fibroblasts. Mol Carcinogenesis 1999;25:262-272.
29. Cip/WAF1 in monocytic differentiation. EMBO J 1999;18:1223-1234.
30. Martinez J, Georgoff I, Martinez J, Levine AJ. Cellular localization and cell cycle regulation by a temperature- sensitive p53 protein. Genes Dev 1991;5:151-159.
31. Dhanwada KR, Dickens M, Neades R, Davis R, Pelling JC. Differential effects of UV-B and UV-C components of solar radiation on MAP kinase signal transduction pathways in epidermal keratinocytes. Oncogene 1995;11:1947-1953.
32. Harlow E, Lane D. Antibodies: A Laboratory Manual. New York: Cold Spring Harbor Laboratory Press; 1998. 521 p.
33. Ilchijo H, Nishida E, Irie K, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997;275:90-94.